Founded in July 2014 by Dr. Tian Hongqi, Lilly Asia Ventures and Morningside, Shanghai Kechow Pharma, Inc. is an innovative drug research and development enterprises emerging from the foundation of Tianjin Binjiang Pharma, Inc. It focuses primarily on the R&D of innovative anti-cancer drugs, aiming to provide high-quality, innovative best-in-class treatments to address clinical needs. As a biopharmaceutical company, it receives particular support from the Shanghai government. 

Kechow Pharma is dedicated to the R&D of small molecule anti-cancer drugs. Tian Hongqi, Founder and Chairman of Kechow Pharma, expressed gratitude for the recognition and support from prominent global institutional investors focusing on biopharmaceuticals. He said: “This round of financing will accelerate our innovative drug research and the clinical development of our pipeline products, particularly the clinical research and marketing application of our MEK inhibitor, HL-085, in the U.S. and China. As an innovation-driven company, our mission is to develop best-in-class drugs to meet clinical needs, while also attracting and nurturing exceptional talents to strengthen our team. We aim to grow Kechow Pharma into a leading force in the R&D of innovative drugs.”